Literature DB >> 25877059

Cognitive impairment in multiple sclerosis: An 18 year follow-up study.

Lauren B Strober1, Stephen M Rao2, Jar-Chi Lee2, Elizabeth Fischer2, Richard Rudick2.   

Abstract

BACKGROUND: Cognitive impairment occurs in 40-65% of patients with multiple sclerosis (MS). Less is known about the rate and pattern of cognitive decline over the course of the illness.
OBJECTIVE: To examine long-term changes in cognition among patients enrolled in the phase III clinical trial of intramuscular interferon beta-1a (IM IFNβ-1a).
METHODS: Twenty-two patients underwent a longitudinal investigation comparing neuropsychological test performance at study entry and 18-year follow-up.
RESULTS: Over the 18 year interval, significant declines were observed on measures of information processing speed, simple and complex auditory attention, episodic learning and memory, and visual construction. Nine patients (41%) were found to be cognitively impaired at study entry. At follow-up 13 patients (59%) were cognitively impaired. While both the impaired and unimpaired patients at baseline experienced declines on these measures, only one measure, the Symbol Digit Modalities Test (SDMT), demonstrated a group (cognitively impaired versus intact at baseline)×time interaction. This interaction was characterized by a steeper decline in the unimpaired than the impaired group at baseline.
CONCLUSIONS: Over an 18 year period, our results suggest that cognitive impairment in MS progresses, with declines being most evident on measures known to be most sensitive to MS-related cognitive difficulties both cross-sectionally and longitudinally.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognition; Longitudinal investigation; Multiple sclerosis

Year:  2014        PMID: 25877059     DOI: 10.1016/j.msard.2014.03.004

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  12 in total

1.  A longitudinal study of cognitive function in multiple sclerosis: is decline inevitable?

Authors:  Marina Katsari; Dimitrios S Kasselimis; Erasmia Giogkaraki; Marianthi Breza; Maria-Eleftheria Evangelopoulos; Maria Anagnostouli; Elisabeth Andreadou; Costas Kilidireas; Alia Hotary; Ioannis Zalonis; Georgios Koutsis; Constantin Potagas
Journal:  J Neurol       Date:  2020-02-01       Impact factor: 4.849

Review 2.  Social Cognition in Multiple Sclerosis: a Meta-Analysis.

Authors:  Emre Bora; Serkan Özakbaş; Dennis Velakoulis; Mark Walterfang
Journal:  Neuropsychol Rev       Date:  2016-06-20       Impact factor: 7.444

3.  Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey.

Authors:  Ann D Bass; Bart Van Wijmeersch; Lori Mayer; Mathias Mäurer; Aaron Boster; Matt Mandel; Colin Mitchell; Kersten Sharrock; Barry Singer
Journal:  Int J MS Care       Date:  2019-08-28

4.  Preserved canonicality of the BOLD hemodynamic response reflects healthy cognition: Insights into the healthy brain through the window of Multiple Sclerosis.

Authors:  Monroe P Turner; Nicholas A Hubbard; Dinesh K Sivakolundu; Lyndahl M Himes; Joanna L Hutchison; John Hart; Jeffrey S Spence; Elliot M Frohman; Teresa C Frohman; Darin T Okuda; Bart Rypma
Journal:  Neuroimage       Date:  2018-02-15       Impact factor: 6.556

5.  Cognition in older patients with multiple sclerosis compared to patients with amnestic mild cognitive impairment and healthy older adults.

Authors:  Alexandra K Roth; Douglas R Denney; Jeffrey M Burns; Sharon G Lynch
Journal:  Neuropsychology       Date:  2018-06-25       Impact factor: 3.295

6.  Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.

Authors:  Ingo Kleiter; Michael Lang; Judith Jeske; Christiane Norenberg; Barbara Stollfuß; Markus Schürks
Journal:  BMC Neurol       Date:  2017-09-06       Impact factor: 2.474

Review 7.  The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

Authors:  Nicholas G LaRocca; Lynn D Hudson; Richard Rudick; Dagmar Amtmann; Laura Balcer; Ralph Benedict; Robert Bermel; Ih Chang; Nancy D Chiaravalloti; Peter Chin; Jeffrey A Cohen; Gary R Cutter; Mat D Davis; John DeLuca; Peter Feys; Gordon Francis; Myla D Goldman; Emily Hartley; Raj Kapoor; Fred Lublin; Gary Lundstrom; Paul M Matthews; Nancy Mayo; Richard Meibach; Deborah M Miller; Robert W Motl; Ellen M Mowry; Rob Naismith; Jon Neville; Jennifer Panagoulias; Michael Panzara; Glenn Phillips; Ann Robbins; Matthew F Sidovar; Kathryn E Smith; Bjorn Sperling; Bernard Mj Uitdehaag; Jerry Weaver
Journal:  Mult Scler       Date:  2017-08-11       Impact factor: 6.312

8.  Research-to-Practice Gaps in Multiple Sclerosis Care for Patients with Subjective Cognitive, Mental Health, and Psychosocial Concerns in a Canadian Center.

Authors:  Lisa A S Walker; Courtney Gardner; Mark S Freedman; Heather MacLean; Carolina Rush; Marjorie Bowman
Journal:  Int J MS Care       Date:  2019 Nov-Dec

9.  Compromised Motor Dexterity Confounds Processing Speed Task Outcomes in Stroke Patients.

Authors:  Essie Low; Sheila Gillard Crewther; Ben Ong; Diana Perre; Tissa Wijeratne
Journal:  Front Neurol       Date:  2017-09-21       Impact factor: 4.003

10.  Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.

Authors:  Stanley Cohan; Ludwig Kappos; Gavin Giovannoni; Heinz Wiendl; Krzysztof Selmaj; Eva Kubala Havrdová; John Rose; Steven Greenberg; Glenn Phillips; Wei Ma; Ping Wang; Gabriel Lima; Guido Sabatella
Journal:  Mult Scler       Date:  2017-10-06       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.